Article Text

Download PDFPDF

Chemokines in joint disease: the key to inflammation?
  1. J J Haringman,
  2. J Ludikhuize,
  3. P P Tak
  1. Division of Clinical Immunology and Rheumatology, Academic Medical Centre/University of Amsterdam, The Netherlands
  1. Correspondence to:
    Dr P P Tak
    Division of Clinical Immunology and Rheumatology, F4-218, Department of Internal Medicine, Academic Medical Centre/University of Amsterdam, Meibergdreef 9, NL-1105 AZ Amsterdam, The Netherlands;


Targeting chemokines and/or chemokine receptors appears to be an intriguing new approach to treating chronic inflammatory disorders like rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis, and transplant rejections. The involvement of chemokines and chemokine receptors in inflammatory joint diseases, the in vitro and in vivo characteristics of the chemokine family in inflammatory joint disease, and initial clinical data on chemokine blockade in patients with rheumatoid arthritis suggest that targeting the chemokine and chemokine receptor family might provide a new, promising antirheumatic strategy.

  • IL, interleukin
  • MCP, monocyte chemoattractant protein
  • OA, osteoarthritis
  • PsA, psoriatic arthritis
  • RA, rheumatoid arthritis
  • SF, synovial fluid
  • ST, synovial tissue
  • TNFα, tumour necrosis factor α
  • rheumatoid arthritis
  • chemokines
  • synovium

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.